FDA-approved
Skin & aging
Afamelanotide
Evidence
FDA approved
Class
Melanocortin 1 receptor agonist
KEY TAKEAWAY
Afamelanotide is a melanocortin peptide implant approved to help adults with erythropoietic protoporphyria tolerate sunlight. It increases melanin and reduces pain from light exposure.
Written by the Veylo editorial team · Updated
November 2026
What it is
A synthetic copy of alpha-MSH delivered as an implant
Approved for
Light-triggered pain in erythropoietic protoporphyria
Key fact
Increased pain-free time in sunlight in a randomized trial
Route
Implant under the skin
Evidence strength
FDA approved
Afamelanotide, sold as Scenesse, is a synthetic analog of alpha-melanocyte-stimulating hormone. It comes as a small implant placed under the skin about every two months.
It activates the melanocortin 1 receptor on pigment cells, increasing skin melanin and helping protect from light-driven damage.
The FDA approved afamelanotide in 2019 for adults with erythropoietic protoporphyria.
Reducing phototoxic reactions in adults with erythropoietic protoporphyria.
Nausea, headache, implant-site reactions and darkening of skin or moles can occur. Regular skin checks are recommended.
Langendonk JG et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373:48-59.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.